{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:26Z","timestamp":1786982666947,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13555-016-0122-9","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T03:23:03Z","timestamp":1465615383000},"page":"397-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis"],"prefix":"10.1007","volume":"6","author":[{"given":"Victoria M.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Maranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,11]]},"reference":[{"issue":"5 Pt 1","key":"122_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0190-9622(95)91846-9","volume":"33","author":"TG Berger","year":"1995","unstructured":"Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol. 1995;33(5 Pt 1):837\u20138. doi: 10.1016\/0190-9622(95)91846-9 .","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"122_CR2","first-page":"233","volume":"23","author":"P Herranz","year":"1998","unstructured":"Herranz P, Pizarro A, de Lucas R, et al. Treatment of AIDS-associated prurigo nodularis with thalidomide. Clin Exp Dermatol. 1998;23(5):233\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"122_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1440-0960.2005.00187.x","volume":"46","author":"MR Lee","year":"2005","unstructured":"Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol. 2005;46(4):211\u201320. doi: 10.1111\/j.1440-0960.2005.00187.x .","journal-title":"Australas J Dermatol"},{"issue":"7","key":"122_CR4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1001\/archderm.140.7.845","volume":"140","author":"T Maurer","year":"2004","unstructured":"Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;140(7):845\u20139. doi: 10.1001\/archderm.140.7.845 .","journal-title":"Arch Dermatol"},{"issue":"4","key":"122_CR5","first-page":"221","volume":"64","author":"M Saco","year":"2015","unstructured":"Saco M, Cohen G. Prurigo nodularis: picking the right treatment. J Fam Pract. 2015;64(4):221\u20136.","journal-title":"J Fam Pract"},{"key":"122_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","volume":"6","author":"J Sheskin","year":"1965","unstructured":"Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"122_CR7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","volume":"153","author":"JJ Wu","year":"2005","unstructured":"Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanismis of action and side effects. Br J Dermatol. 2005;153:254\u201373.","journal-title":"Br J Dermatol"},{"issue":"8","key":"122_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1517\/13543784.6.8.1105","volume":"6","author":"JB Marriott","year":"1997","unstructured":"Marriott JB. TNF-alpha antagonists: monoclonal antibodies, soluble receptors, thalidomide and other novel approaches. Expert Opin Investig Drugs. 1997;6(8):1105\u20138. doi: 10.1517\/13543784.6.8.1105 .","journal-title":"Expert Opin Investig Drugs"},{"key":"122_CR9","doi-asserted-by":"crossref","unstructured":"McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol. 1997;110(2):151\u2013154. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2265499&tool=pmcentrez&rendertype=abstract . Accessed 15 Nov 2015.","DOI":"10.1111\/j.1365-2249.1997.tb08310.x"},{"issue":"3","key":"122_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1684\/ecn.2013.0342","volume":"24","author":"B Piura","year":"2013","unstructured":"Piura B, Medina L, Rabinovich A, Dyomin V, Huleihel M. Thalidomide distinctly affected TNF-\u03b1, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells. Eur Cytokine Netw. 2013;24(3):122\u20139. doi: 10.1684\/ecn.2013.0342 .","journal-title":"Eur Cytokine Netw"},{"key":"122_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neuint.2015.04.006","volume":"85\u201386","author":"T Song","year":"2015","unstructured":"Song T, Wang L, Gu K, et al. Involvement of peripheral TRPV1 channels in the analgesic effects of thalidomide. Neurochem Int. 2015;85\u201386:40\u20135. doi: 10.1016\/j.neuint.2015.04.006 .","journal-title":"Neurochem Int"},{"issue":"2","key":"122_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140\u201356. doi: 10.1002\/bdrc.21096 .","journal-title":"Birth Defects Res C Embryo Today."},{"issue":"11","key":"122_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","volume":"9","author":"GW Muller","year":"1999","unstructured":"Muller GW, Chen R, Huang S-Y, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-\u03b1 production. Bioorg Med Chem Lett. 1999;9(11):1625\u201330. doi: 10.1016\/S0960-894X(99)00250-4 .","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"122_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archdermatol.2011.2918","volume":"148","author":"H Kanavy","year":"2012","unstructured":"Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol. 2012;148(7):794. doi: 10.1001\/archdermatol.2011.2918 .","journal-title":"Arch Dermatol"},{"key":"122_CR15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000245988","volume":"195","author":"C Ferrandiz","year":"1997","unstructured":"Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology. 1997;195:359\u201361.","journal-title":"Dermatology"},{"issue":"5","key":"122_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archderm.1980.01640290081018","volume":"116","author":"H Broek van den","year":"1980","unstructured":"van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol. 1980;116(5):571\u20132. doi: 10.1001\/archderm.1980.01640290081018 .","journal-title":"Arch Dermatol"},{"issue":"5","key":"122_CR17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/0001555564412417","volume":"64","author":"RK Winkelmann","year":"1984","unstructured":"Winkelmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol. 1984;64(5):412\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"122_CR18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1985.tb02323.x","volume":"112","author":"CH Wulff","year":"1985","unstructured":"Wulff CH, H\u00f8yer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol. 1985;112(4):475\u201380.","journal-title":"Br J Dermatol"},{"issue":"4","key":"122_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1440-0960.2002.00593.x","volume":"43","author":"RB Crouch","year":"2002","unstructured":"Crouch RB, Foley PA, Ng JCH, Baker CS. Thalidomide experience of a major Australian teaching hospital. Australas J Dermatol. 2002;43(4):278\u201384. doi: 10.1046\/j.1440-0960.2002.00593.x .","journal-title":"Australas J Dermatol."},{"issue":"5","key":"122_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1046\/j.1365-4362.2003.01184.x","volume":"42","author":"A Alfadley","year":"2003","unstructured":"Alfadley A, Al-Hawsawi K, Thestrup-Pedersen K, Al-Aboud K. Treatment of prurigo nodularis with thalidomide: a case report and review of the literature. Int J Dermatol. 2003;42(5):372\u20135. doi: 10.1046\/j.1365-4362.2003.01184.x .","journal-title":"Int J Dermatol"},{"key":"122_CR21","doi-asserted-by":"publisher","unstructured":"Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatol Treat. 2007;18(0954-6634 (Print)):335\u2013340. doi: 10.1080\/09546630701386993 .","DOI":"10.1080\/09546630701386993"},{"issue":"4","key":"122_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1346-8138.2007.00260.x","volume":"34","author":"CCE Lan","year":"2007","unstructured":"Lan CCE, Lin CL, Wu CS, Chai CY, Chen WT, Chen GS. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol. 2007;34(4):237\u201342. doi: 10.1111\/j.1346-8138.2007.00260.x .","journal-title":"J Dermatol"},{"issue":"8","key":"122_CR23","first-page":"769","volume":"7","author":"SD Doherty","year":"2008","unstructured":"Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol. 2008;7(8):769\u201373.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"122_CR24","first-page":"141","volume":"13","author":"A Orlando","year":"2009","unstructured":"Orlando A, Renna S, Cottone M. Prurigo nodularis of hyde treated with low-dose thalidomide. Eur Rev Med Pharmacol Sci. 2009;13(2):141\u20135.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"2","key":"122_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000331577","volume":"223","author":"TP Andersen","year":"2011","unstructured":"Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology. 2011;223(2):107\u201312. doi: 10.1159\/000331577 .","journal-title":"Dermatology"},{"issue":"3","key":"122_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2340\/00015555-0997","volume":"91","author":"H Taefehnorooz","year":"2011","unstructured":"Taefehnorooz H, Truchetet F, Barbaud A, Schmutz JL, Bursztejn AC. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol. 2011;91(3):344\u20135. doi: 10.2340\/00015555-0997 .","journal-title":"Acta Derm Venereol"},{"key":"122_CR27","unstructured":"Liu H, Gaspari AA, Schleichert R. Use of lenalidomide in treating refractory prurigo nodularis. J Drugs Dermatol. 2013;12(3):360\u2013361. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23545923 . Accessed 6 July 2015."},{"issue":"6","key":"122_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.anai.2014.09.010","volume":"113","author":"R Rishi","year":"2014","unstructured":"Rishi R, Ringwala S, Tracy J, Fatteh S. Prurigo nodularis and Hashimoto thyroiditis. Ann Allergy Asthma Immunol. 2014;113(6):673\u20134. doi: 10.1016\/j.anai.2014.09.010 .","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"122_CR29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archderm.1984.01650390060012","volume":"120","author":"OJ Clemmensen","year":"1984","unstructured":"Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol. 1984;120(3):338\u201341.","journal-title":"Arch Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0122-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T11:09:21Z","timestamp":1718622561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0122-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0122-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,11]]}}}